Serum levels of IL-17A in patients with relapsing-remitting multiple sclerosis treated with interferon-Beta

In this study, researchers looked at the relationship between nonresponders (NR) and interleukin-17 (IL-17A) serum titres, as well as binding antibodies (BAbs) to interferon-β (IFN-β) therapy. IL-17A is a proinflammatory cytokine which is involved in the pathogenesis of MS.

From their cohort of 72 people with relapsing-remitting MS treated for at least 18 months with IFN-β, 37.5% were NR and had a significantly higher serum IL-17A level when compared to the responder group. Also, 26.4% were IL-17A positive and had a higher number of relapses in the 12 months previously, in addition to a higher Expanded Disability Status Scale (EDSS).

Authors: Balasa R, Bajko Z, Hutanu A

Source: Mult Scler. 2012 Dec 3. [Epub ahead of print]

Read the abstract



Latest MS research news

Main MS research areas

Challenges of MS research

Atacicept in multiple sclerosis: a randomised, placebo-controlled, double-blind, phase 2 trial